Trial
NCT03489265
Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Allergan
Condition
Fecal Incontinence
Intervention
Eluxadoline 100 mg
Why stopped
Difficult to recruit severely affected patients with fecal incontinence
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-25